Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Patient Access Network Foundation and the National Parkinson Foundation Announce New Alliance to Provide Support for People Living With Parkinson’s Disease

Washington, DC — The Patient Access Network (PAN) Foundation and the National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, today announced they are launching a new alliance to offer a broad range of support for people living with Parkinson’s disease. Working together, the PAN Foundation and the NPF will ensure that people living with Parkinson’s disease have access to both financial and patient support services, providing them with the holistic support needed to best manage their disease.

“At PAN, we work to alleviate some of the financial burden that patients and families face with diseases like Parkinson’s,” said PAN President and CEO Dan Klein. “But we know that financial concerns are just part of the challenge faced by people with Parkinson’s. In working with the National Parkinson Foundation, we can connect patients to additional services, including a national helpline, educational materials, online forums with experts, a resource library and more.”

According to the American Academy of Neurology, Parkinson’s disease affects about 1 million Americans, with at least 60,000 new cases reported each year.

“We are excited to kick off this partnership with the PAN Foundation, and provide extended support for our patients and families,” said Paul Blom, Interim CEO of the National Parkinson Foundation. “Parkinson’s disease is a complex, long-term disease that can be stressful and overwhelming for patients and their families. By partnering with PAN, we can help to ease some of the financial pressure for those who need it most.”

Patients who qualify for the PAN Foundation’s Parkinson’s Disease program are eligible to receive up to $16,500 per year in financial assistance. Eligible patients must be getting treatment for Parkinson’s Disease; must reside and receive treatment in the United States; must have Medicare health insurance; and the medication for which they seek assistance must be covered by Medicare and must treat the disease directly. In addition, patients must fall at or below 500 percent of the Federal Poverty Level.

Patients, or advocates and caregivers applying on their behalf, can apply for assistance using the PAN Foundation’s online patient portal (www.panapply.org), or by calling 1-866-316-7263, 9 a.m. to 5 p.m. Eastern Time, Monday through Friday. To learn more about PAN’s more than 50 disease-specific programs, visit panfoundation.org.

About the PAN Foundation:

The PAN Foundation is an independent, nationwide 501(c)3 organization dedicated to providing help and hope to underinsured patients who are unable to afford the out-of-pocket expenses for their prescribed medications. Since 2004, PAN has provided nearly $2.4 billion in financial assistance to more than 605,000 patients who would otherwise be unable to afford their medications. To learn more, visit www.panfoundation.org.

Thursday, October 20, 2016
Parkinson's Foundation Study Finds Gender Disparities in Caregiving, with Women at a Disadvantage
Monday, December 4, 2017

Largest Clinical Study Tracking Parkinson’s Patients Over Time Shows Women with Parkinson’s Have Fewer Caregiving Resources than Men with Parkinson’s

Parkinson’s Foundation Invests $60,000 to Develop Innovative Models of Patient Engagement
Wednesday, November 29, 2017

Six Awards Foster Patient-Driven Parkinson’s Research

Jesse Jackson Diagnosed with Parkinson's Disease
Friday, November 17, 2017

Rev. Jesse Jackson’s announcement today that he has been living with Parkinson’s Disease since 2015 further proves that receiving a diagnosis of Parkinson's is not a death sentence. There are many ways that people living with Parkinson's can control the symptoms of the disease with exercise and physical therapy to help maintain mobility and balance.

Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger
Thursday, October 26, 2017

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

Parkinson’s Foundation Welcomes Two New Board Members
Tuesday, October 24, 2017

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

Parkinson's Foundation Unveils New Brand and Website
Thursday, October 19, 2017

NEW YORK and MIAMI /PRNewswire-USNewswire/ — The Parkinson's Foundation today announced the launch of its new brand and website following the recent merger of two legacy organizations – National Parkinson Foundation and Parkinson's Disease Foundation – as part of its mission to

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia
Friday, August 25, 2017

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

Parkinson’s Foundation Announces $1.2 Million Investment to Advance Careers, Support Innovation of Early Career Parkinson’s Scientists
Tuesday, August 8, 2017

NEW YORK & MIAMI The Parkinson's Foundation is pleased to announce a $1.2 million investment in 27 career development and fellowship grants to support the work of promising early career scientists in the field of Parkinson's.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.